It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Very long-chain fatty acids (VLCFA) are critical for human cytomegalovirus replication and accumulate upon infection. Here, we used Epstein-Barr virus (EBV) infection of human B cells to elucidate how herpesviruses target VLCFA metabolism. Gene expression profiling revealed that, despite a general induction of peroxisome-related genes, EBV early infection decreased expression of the peroxisomal VLCFA transporters ABCD1 and ABCD2, thus impairing VLCFA degradation. The mechanism underlying ABCD1 and ABCD2 repression involved RNA interference by the EBV-induced microRNAs miR-9-5p and miR-155, respectively, causing significantly increased VLCFA levels. Treatment with 25-hydroxycholesterol, an antiviral innate immune modulator produced by macrophages, restored ABCD1 expression and reduced VLCFA accumulation in EBV-infected B-lymphocytes, and, upon lytic reactivation, reduced virus production in control but not ABCD1-deficient cells. Finally, also other herpesviruses and coronaviruses target ABCD1 expression. Because viral infection might trigger neuroinflammation in X-linked adrenoleukodystrophy (X-ALD, inherited ABCD1 deficiency), we explored a possible link between EBV infection and cerebral X-ALD. However, neither immunohistochemistry of post-mortem brains nor analysis of EBV seropositivity in 35 X-ALD children supported involvement of EBV in the onset of neuroinflammation. Collectively, our findings indicate a previously unrecognized, pivotal role of ABCD1 in viral infection and host defence, prompting consideration of other viral triggers in cerebral X-ALD.
Using Epstein-Barr virus (EBV) infection of human B cells, the importance of peroxisomal very long-chain fatty acid transport involving ABCD1 in viral infection and host defence is elucidated and applicable also to other herpes- and coronaviruses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Medical University of Vienna, Department of Pathobiology of the Nervous System, Center for Brain Research, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
2 Medical University of Vienna, Department of Pathobiology of the Nervous System, Center for Brain Research, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492); University of Glasgow, Institute of Molecular, Cell and Systems Biology, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
3 Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
4 Medical University of Vienna, Division of Neuropathology and Neurochemistry, Department of Neurology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
5 Hugo W. Moser Research Institute at Kennedy Krieger, Kennedy Krieger Institute, Department of Neurogenetics, Baltimore, USA (GRID:grid.240023.7) (ISNI:0000 0004 0427 667X)
6 Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
7 University of Amsterdam, Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
8 Medical University of Vienna, Department of Neuroimmunology, Center for Brain Research, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
9 University Hospital Leipzig, Department of Pediatric Oncology, Hematology, and Hemostaseology, Leipzig, Germany (GRID:grid.411339.d) (ISNI:0000 0000 8517 9062)